Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 14, 2018

Primary Completion Date

November 14, 2019

Study Completion Date

August 13, 2020

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

Pegcetacoplan

Complement (C3) Inhibitor

DRUG

Soliris

Complement (C5) Inhibitor

Trial Locations (53)

1200

Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert

3000

Royal Melbourne Hospital, Melbourne

8800

AZ Delta Campus Wilgenstraat, Roeselare

10469

New York Cancer & Blood Specialists, The Bronx

11733

New York Cancer & Blood Specialists, East Setauket

13009

Institut Paoli-Calmettes Marseille, Marseille

14263

Roswell Park Cancer Institute, Buffalo

14584

Soonchunhyang University Bucheon Hospital, Bucheon-si

20057

Georgetown University Hospital, Washington D.C.

20246

Universitätsklinikum Hamburg Eppendorf, Hamburg

27710

Duke University Medical Center, Durham

30322

Winship Cancer Institute of Emory University, Atlanta

31059

Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse

32256

Cancer Specialists of North Florida, Jacksonville

32763

Mid Florida Hematology and Oncology, Orange City

33014

Lakes Research, Miami Lakes

35010

Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria

35015

Chungnam National University Hospital, Daejeon

37920

University of Tennessee Medical Center, Knoxville

38120

Baptist Cancer Center, Memphis

45147

Universitätsklinikum Essen, Essen

46026

Hospital Universitario Politécnico La Fe, Valencia

46260

Investigative Clinical Research of Indiana, Indianapolis

49503

Cancer & Hematology Centers of Western Michigan, Grand Rapids

52074

Uniklinik RWTH Aachen, Aachen

59037

Centre Hospitalier Universitaire de Lille, Lille

60611

Northwestern University, Chicago

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

71100

Centre Hospitalier William Morey, Chalon-sur-Saône

74374

Centre Hospitalier Annecy Genevois, Annecy

75010

Hôpital Saint-Louis, Paris

75701

HOPE Cancer Center of East Texas, Tyler

80204

Denver Health, Denver

89081

Universitätsklinikum Ulm, Ulm

90033

University of Southern California, Los Angeles

90403

Sarcoma Oncology Research Center, Santa Monica

97330

Good Samaritan Hospital, Corvallis

197022

Pavlov First Saint Petersburg State Medical University of Russian Ministry of Health, Saint Petersburg

Pavlov First Saint Petersburg State Medical University, Saint Petersburg

625023

Institution of Health Care of Tyumen Region, Tyumen

T6G 2G3

University of Alberta, Edmonton

M9A1G2

Toronto General Hospital, Toronto

02321

Centre Hospitalier de Saint-Quentin, Saint-Quentin

453-8511

Japanese Red Cross Nagoya Daiichi Hospital, Nagoya

453-8650

Japanese Red Cross Nagoya Daini Hospital, Showa-ku

305-8576

University of Tsukuba Hospital, Tsukuba

390-8621

Shinshu University Hospital, Matsumoto

700-8558

Okayama University Hospital, Okayama

113-8421

Juntendo University Hospital, Bunkyo-ku

141-8625

NTT Medical Center Tokyo, Shinagawa-ku

646-8588

Kinan Hospital, Tanabe

06351

Samsung Medical Center, Seoul

LS9 7TF

St. James' Institute of Oncology, Leeds Teaching Hospitals, Leeds

Sponsors
All Listed Sponsors
lead

Apellis Pharmaceuticals, Inc.

INDUSTRY